Table 3.

Adverse events during lenvatinib therapy.

	Any grades	Grade ≥ 3	Any grades		grade ≥ 3		p	p
	(All patients, n = 25)	(All patient n = 25)	Non muscle loss during 3 months lenvatinib n = 6*	Muscle loss during 3 months lenvatinib n = 15*	Non muscle loss during 3 months lenvatinib n = 6*	Muscle loss during 3 months lenvatinib n = 15*	Any grade	grade ≥ 3
Total treatment related AEs	25 (100%)	15 (60%)	6 (100%)	15 (100%)	5 (83.3%)	5 (33.3%)	–	0.0635
Fatigue	16 (64%)	2 (8%)	5 (83.3%)	7 (46.7%)	1 (16.7%)	0	0.1778	0.2857
Decreased weight	4 (16%)	1 (4%)	0	4 (26.7%)	0	1 (6.7%)	0.2807	1
Mucositis	8 (32%)	1 (4%)	4 (66.7%)	3 (20%)	1 (16.7%)	0	1	0.2857
Diarrhoea	7 (28%)	2 (8%)	2 (33.3%)	5 (93.3%)	1 (16.7%)	1 (6.7%)	1?	0.500
Hypertension	7 (28%)	0	2 (33.3%)	4 (26.7%)	0	0	1	–
Decreased appetite	7 (28%)	0	2 (33.3%)	3 (20%)	0	0	0.5975	–
Polyneuropathy/tremor	5 (20%)	0	1 (16.7%)	4 (26.7%)	0	0	1	–
Infection	6 (24%)	3 (12%)	2 (33.3%)	2 (13.3%)	1 (16.7%)	1 (6.7%)	0.5439	0.500
Vertigo	4 (16%)	0	1 (16.6%)	2 (13.3%)	0	0	1	–
Pain	6 (24%)	1 (4%)	0	4 (26.7%)	0	0	0.2807	–
Proteinuria	4 (16%)	0	2 (33.3%)	2 (13.3%)	0	0	0.5439	–
Liver funtion disorder Elevated AST/ALT	3 (12%)	2 (8%)	0	2 (13.3%)	0	1 (6.7%)	1	1
Nausea	3 (12%)	0	1 (16.7%)	2 (13.3%)	0	0	1	–
Dyspnoe	2 (8%)	0	0	1 (6.7%)	0	0	1	-–
Neutropenia	2 (8%)	1 (4%)	1 (16.7%)	1 (6.7%)	1 (16.7%)	0	0.500	0.2857
decreased platelet count	2 (8%)	1 (4%)	1 (16.7%)	1 (6.7%)	0	1 (6.7%)	0.500	1
Arterial lung embolie	2 (8%)	2 (8%)	2 (33.3%)	0	2 (33.3%)	0	0.0714	0.0714
Pleura effusion/edema	2 (8%)	0	0	2 (13.3%)	0	0	1	–
Constipation	1 (4%)	0	0	1 (6.7%)	0	0	1	–
Hand-foot syndrome	1 (4%)	0	0	1 (6.7%)	0	0	1	–
Pruritus	1 (4%)	0	0	1 (6.7%)	0	0	1	–
hepatic encephalopathy	1 (4%)	0	0	1 (6.7%)	0	0	1	–
Increased Bilirubin/INR	1 (4%)	1 (4%)	0	1 (6.7%	0	1 (6.7%)	1	1

Numbers are presented as n (%).

The table includes treatment-related adverse events (AEs) of any grades and grade ≥ 3, observed during treatment with lenvatinib.

*Only 21 patients were evaluated, since four patients died before first CT staging.